In previous grant cycles, the ADCS has not played a major role in biomarker measurement;assays for Apolipoprotein E (ApoE) genotype, and for plasma and CSF measurement of amyloid peptides and tau proteins have been subcontracted to companies or external academic labs. However, the importance of biomarker measurement has grown steadily, in part due to the success of the Alzheimer's Disease Neuroimaging Initiative. There have been an increasing number of requests for stored ADCS samples, and increasing requests for biomarker measurement from ADCS investigators. To meet these needs, in late 2008, we established a Biomarker Core which is located on the 3rd floor of the Medical Teaching Facility building at UCSD School of Medicine.
The goal of the laboratory is to identify biomarkers for preclinical AD and better understand how treatment parameters may impact these biomarkers. In addition to playing a role in ADCS clinical trials, another objective of the Biomarker Core is research based and aims to identify and characterize novel biomarkers of AD. The primary focus of this research is on plasma beta-amyloid.
|Mormino, Elizabeth C; Betensky, Rebecca A; Hedden, Trey et al. (2014) Amyloid and APOE ?4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82:1760-7|
|Mormino, Elizabeth C; Betensky, Rebecca A; Hedden, Trey et al. (2014) Synergistic effect of ?-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71:1379-85|
|Rafii, Michael S; Taylor, Curtis S; Kim, Hyun T et al. (2014) Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen 29:159-65|
|Whitehouse, Peter J (2014) The end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspective. Biochem Pharmacol 88:677-81|
|Burstein, Aaron H; Grimes, Imogene; Galasko, Douglas R et al. (2014) Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol 14:12|
|Donohue, Michael C; Jacqmin-Gadda, Hélène; Le Goff, Mélanie et al. (2014) Estimating long-term multivariate progression from short-term data. Alzheimers Dement 10:S400-10|
|Samieri, Cécilia; Proust-Lima, Cécile; M Glymour, Maria et al. (2014) Subjective cognitive concerns, episodic memory, and the APOE ?4 allele. Alzheimers Dement 10:752-759.e1|
|Galasko, Douglas; Bell, Joanne; Mancuso, Jessica Y et al. (2014) Clinical trial of an inhibitor of RAGE-A? interactions in Alzheimer disease. Neurology 82:1536-42|
|Sperling, Reisa A; Rentz, Dorene M; Johnson, Keith A et al. (2014) The A4 study: stopping AD before symptoms begin? Sci Transl Med 6:228fs13|
|Papay, Kimberly; Xie, Sharon X; Stern, Matthew et al. (2014) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 83:826-33|
Showing the most recent 10 out of 14 publications